Adamas Appoints Anna Richo to Board of Directors
September 01 2020 - 9:15AM
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to
developing and delivering medicines that make a meaningful
difference to people affected by neurological diseases, today
announced the appointment of Anna Richo, J.D., General Counsel,
Chief Compliance Officer, and Corporate Secretary at Cargill, Inc.,
to its Board of Directors. She will also serve on the Audit
Committee. Ms. Richo brings over 30 years of leadership experience
managing legal and compliance functions within the biotechnology
and pharmaceutical industry, including UCB, Amgen, and Baxter
Healthcare as well as prior public-company Board, Audit, and
Finance Committee experience at Cytyc Corporation.
“We are delighted to welcome Anna to our board
during this exciting time of growth for us as a commercial
organization,” said David L. Mahoney, Chairman, Adamas. “Anna
brings extensive and relevant operational expertise, and we look
forward to her contributions as we continue to advance and evolve
Adamas,” added Neil F. McFarlane, CEO.
"I am excited to work with the Adamas Board of
Directors and management team given the company’s strong patient
focus," said Ms. Richo. "I look forward to partnering with the
team to help the company reach its long-term goals and deliver
innovative medicines that reduce the burden of neurological
diseases on patients, caregivers, and society."
Having joined Cargill in 2019, Ms. Richo’s
successful career path includes leadership roles in biotechnology
and pharmaceutical companies as general counsel and leading
compliance, intellectual property, and corporate litigation. Ms.
Richo has previously been recognized as one of the ’Top 15 Women in
Pharma’. She holds a bachelor’s degree in industrial and
labor relations from Cornell University and a J.D. degree from
DePaul University, College of Law. She is a member of the Board of
Trustees for DePaul University.
About AdamasAt Adamas our
vision is clear – to deliver innovative medicines that reduce the
burden of neurological diseases on patients, caregivers, and
society. We are a fully integrated company focused on growing a
portfolio of therapies to address a range of neurological diseases.
For more information, please visit www.adamaspharma.com.
Contact:
Media:Sarah MathiesonVice President of Corporate
Communications510-450-3528smathieson@adamaspharma.com |
Investors:Peter VozzoManaging Director,
Westwicke443-213-0505peter.vozzo@westwicke.com |
|
|
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From May 2024 to Jun 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jun 2023 to Jun 2024